Journalist Hunt

JournalistsPricingBlogs
LoginSign up

Roy Brown - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Roy Brown's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Roy Brown

Roy Brown

Verified

Executive Director, Billings Catholic Radio

Montana

Beats

Primary beats

u.s.Religion

Secondary beats

ConstructionDeconstructionFaithCountry MusicHome buying/selling prepQuebec PoliticsFine Art and Cultural CriticismAnd culture of the CEE region I also cover sportsWineMedTechWealth ManagementFashionManufacturingAIAddiction and recovery

Final Covers

Catholic Media

Doesn’t Cover

Environment & Politics.

Journalist Type

Journalist

Seniority Positions

Executive Director

Industries

Content

Total articles 2

  • Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review

    By Candice L. Garwood, Eugene Applebaum College, Roy Brown Verified, Katherine P. Cabral| ACCP JOURNALS@ 1 INTRODUCTION Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide, accounting for 17.9 million people dying from cardiovascular diseases in 2019, representing 32% of all global deaths.1 These deaths and related ASCVD events like myocardial infarction (MI) and stroke, result from the accumulation of atherosclerotic plaque in the artery walls.

    By Candice L. Garwood, Eugene Applebaum College, Roy Brown Verified, Katherine P. Cabral · ACCP JOURNALS

    Dec. 15, 2024

  • Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management

    By Ibrahim S. Alhomoud, Azita H. Talasaz, Preethi Chandrasekaran, Roy Brown Verified| ACCP JOURNALS@ CONFLICT OF INTEREST STATEMENT Dr. Dixon has received grant funding from Boehringer Ingelheim, Inc. Dr. Mehta has received grant funding from Novartis and Amgen. All other authors declare no conflicts of interest. REFERENCES 1 WHO acceleration plan to stop obesity. 2023. Accessed June 7, 2024. https://www.who.int/publications/i/item/9789240075634 2 Adult Obesity Facts. 2024. Accessed June 7, 2024.

    By Ibrahim S. Alhomoud, Azita H. Talasaz, Preethi Chandrasekaran, Roy Brown Verified · ACCP JOURNALS

    Sep. 03, 2024

  • Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review

    By Candice L. Garwood, Eugene Applebaum College, Roy Brown Verified, Katherine P. Cabral| ACCP JOURNALS@ 1 INTRODUCTION Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide, accounting for 17.9 million people dying from cardiovascular diseases in 2019, representing 32% of all global deaths.1 These deaths and related ASCVD events like myocardial infarction (MI) and stroke, result from the accumulation of atherosclerotic plaque in the artery walls.

    By Candice L. Garwood, Eugene Applebaum College, Roy Brown Verified, Katherine P. Cabral · ACCP JOURNALS

    Dec. 15, 2024

As seen in

Billings Catholic Radio,Accp Journals

Company Info

Billings Catholic Radio